Preparation method and application of RGD peptide modified engineered mononuclear cell or macrophage loaded with attenuated salmonella
By expressing RGD peptides on macrophages and co-culturing with attenuated Salmonella, engineered mononuclear or macrophages loaded with attenuated Salmonella were prepared, which solved the ability and enrichment of Chinese medicine for macrophage therapy. The problem of insufficient performance has achieved efficient and lasting anti-tumor effects and biosafety.
Patent Information
- Application Number
- CN202410946071.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
Existing macrophage therapies face challenges such as high therapeutic dose, limited drug loading capacity, short efficacy of traditional drugs, weak enrichment performance for small tumor foci or metastatic foci, and the possibility of cells remodeling into tumor-promoting M2 macrophages. , limiting its biotransformation and application.
By using lentiviral transduction technology to express RGD peptides on monocytes or macrophages and co-cultured with attenuated Salmonella, engineered monocytes loaded with attenuated Salmonella were prepared to enhance their RGD peptide modifications to improve their Effectiveness on tumor identification, enrichment and anti-tumor.
It significantly improves the tumor recognition and enrichment performance of macrophages, extends the bacterial survival time in the body, achieves long-lasting and powerful anti-cancer treatment, and improves biosafety and treatment window.
Smart Images

Figure CN118910168A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biopharmaceuticals, and in particular to a preparation method and application of an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella. Background Art
[0002] The rapid development of cell therapies, including CAR-T cells, engineered macrophages, and engineered natural killer cells, has greatly enhanced people's understanding of the anti-cancer potential of immune cell therapy (Michael Klichinsky et al., 2020, Nature Biotechnology, 38(8):947; Amin Aalipour et al., 2019, Nature Biotechnology, 37(5):531). These immune cells can penetrate multiple barriers, spontaneously target tumor areas, and show strong anti-cancer effects. Among them, macrophages have great potential due to their easy culture, strong tumor chemotaxis, and drug loading capacity. People have engineered monocytes / macrophages to modify them at the cell membrane level, such as adding HER2-scFv (Michael Klichinsky et al., 2020, Nature Biotechnology, 38(8):947), uPAR (Z.Rao et al., 2023, Adv Healthc Mater, 12(18):e2203356) or uPAR-scFv (H.Dai et al., 2024, J Hepatol), etc., to ultimately enhance the recognition of tumor cells by engineered cells; or combine monocytes / macrophages with nanoparticle drugs such as doxorubicin (L.Yang et al., 2022, ACS Nano, 16(6):9799-9809) and iron oxide (CXLi et al., 2019, 31(15):e1807211) to enhance the inhibitory effect of such cell therapies on tumors. Some macrophage therapies have entered clinical trials for the treatment of various solid tumors (KMMaalej et al., 2023, Mol Cancer, 22(1):20). However, these therapies also face some challenges, such as the high dose of cells required for treatment (up to 10 8 / kg)(Michael Klichinsky et al., 2020, Nature Biotechnology, 38(8):947; A. Lei et al., 2024, Nat Immunol, 25(1):102-116), limited cell drug loading capacity, short duration of efficacy of traditional drugs loaded (L. Liu et al., 2022, Adv Drug Deliv Rev, 183(114136)), relatively weak cell enrichment for micro-tumor foci or metastatic foci, and the possibility that cells in the tumor may be reshaped into tumor-promoting M2 macrophages (L. Liu et al., 2022, Adv Drug Deliv Rev, 183(114136)). These all limit the biotransformation and application of cell therapy. Therefore, there is an urgent need to develop new engineered macrophage therapies with greater translational potential.
[0003] The successful clinical application of live anti-tumor microbial preparations is a major advance in tumor biotherapy (L. Wu et al., 2022, Adv Drug Deliv Rev, 187(114363)). Attenuated Salmonella typhimurium (Seung-Hwan Park et al., 2016, Theranostics, 6(10): 1672-1682), attenuated Listeria monocytogenes (D. Chandra et al., 2013, Br J Cancer, 108(11): 2281-2290), Escherichia coli (Fernando P. Canale et al., 2021, Nature) and BCG (E. Moreo et al., 2023, Nat Commun, 14(1): 6090) are being developed for anti-tumor research in preclinical and clinical settings. These microorganisms use strategies that interfere with host cell defense and protein function to achieve long-term survival in macrophages (P. Walch et al., 2021, Cell Host Microbe, 29 (8): 1316-1332). In addition, due to the immunosuppressive microenvironment and disordered blood vessels, they can also specifically colonize in tumors. With just one injection, these strains can not only proliferate in tumors, but also activate the immune microenvironment in tumors, effectively inhibiting tumor growth (S. Zhou et al., 2018, Nat Rev Cancer, 18 (12): 727-743). Various technologies are currently being improved to enhance the targeting effect of bacteria on solid tumors (L. Wu et al., 2022, Adv Drug Deliv Rev, 187 (114363); Seung-Hwan Park et al., 2016, Theranostics, 6 (10): 1672-1682). The durable efficacy and robust activation of immune responses after a single dose suggest that live microbial agents can synergistically enhance macrophage-based antitumor therapy.
[0004] Macrophages have strong chemotactic motility to various solid tumors under the action of intrinsic targeting ligands. However, in smaller tumor foci, such as lung tumor metastases, the weakening of chemokine gradients will lead to a weakening of the recruitment effect, thus affecting this enrichment (F. Combes et al., 2020, J Control Release, 327: 70-87; HW Lee et al., 2013, Biochimica et biophysica acta, 1835 (2): 170-179). RGD peptide can effectively bind to αvβ3 highly expressed on tumor cells (LJ Dooling et al., 2023, Nat Biomed Eng, 7(9): 1081-1096), and is widely used in the visualization and elimination of various tumors and metastases (such as lung cancer and breast cancer) (H. Javid et al., 2024, Cancer Med, 13(2): e6800; EA Egorova and MP Nikitin, 2022, Int J Mol Sci, 23(22)). So, can we first modify the membrane surface of monocytes / macrophages (for example, construct macrophages that can produce RGD peptides on the outer membrane surface) to obtain engineered macrophages with stronger tumor recognition and enrichment performance; further, use the engineered cells to transport live anti-tumor bacteria (intracellular bacteria can survive for a long time) to enhance the higher enrichment of cells and bacteria in the tumor, and use the released bacteria to achieve long-lasting and effective anti-cancer treatment. Compared with direct injection of single engineered cells, loading anti-tumor bacteria activates the anti-cancer phenotype of macrophages with the help of bacterial stimulation. The strains released into the tumor will also exert a strong anti-cancer effect; compared with direct injection of bacteria, this strategy of camouflage and tumor-targeted delivery mediated by engineered macrophages significantly increases the intratumoral concentration and biocompatibility of the strains, thereby expanding the therapeutic window of traditional microbial immunotherapy. The present invention provides an optimized immune cell carrier construction and application strategy, and an effective method based on this strategy to improve the safety and effectiveness of cell / bacterial anti-tumor therapy. Summary of the invention
[0005] In order to solve the problems of the prior art, the present invention provides a preparation method and application of an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella.
[0006] In order to achieve the above application objectives, the technical solutions adopted in this application are as follows: In the first aspect, this application provides a method for preparing an engineered monocyte or macrophage loaded with attenuated Salmonella modified by RGD peptide; In the second aspect, this application provides an engineered monocyte or macrophage loaded with attenuated Salmonella modified by RGD peptide; In the third aspect, this application provides an application of an engineered monocyte or macrophage loaded with attenuated Salmonella modified by RGD peptide in the preparation of an anti-tumor drug. In the fourth aspect, this application provides a combined application of an engineered monocyte or macrophage loaded with attenuated Salmonella modified by RGD peptide and other conventional anti-tumor drugs or methods.
[0007] The method for preparing an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella of the present invention comprises the following steps:
[0008] (1) using lentiviral transduction technology to package, infect, and screen the virus to transform wild-type monocytes or macrophages into genetically engineered cells that can express RGD peptides on the cell outer membrane surface;
[0009] (2) co-culturing the genetically engineered cells with attenuated Salmonella typhimurium at a MOI ratio of 1-100 for 20-120 minutes to obtain RGD-modified engineered cells loaded with attenuated Salmonella, namely, RGD peptide-modified engineered monocytes or macrophages loaded with attenuated Salmonella.
[0010] Furthermore, in step (1), the monocyte / macrophage cell lines used for RGD peptide modification and intracellular strain loading include but are not limited to any one of THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, RAW264.7, J774.1, Ana-1, iBMDM, U937, and mouse / human primary monocytes / macrophages.
[0011] Furthermore, in step (1), the monocytes are any one of the monocytic cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, and primary monocytes derived from bone marrow, peripheral blood or stem cells, and the macrophages are any one of the macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, and primary monocytes derived from bone marrow, peripheral blood, peritoneal cavity or stem cells.
[0012] Furthermore, in step (1), the RGD peptide is arginine-glycine-aspartic acid, which can specifically bind to the αvβ3 receptor highly expressed in tumor cells; the lentiviral solution prepared by packaging with 293T / 293FT cells is co-incubated with monocytes or macrophages to prepare RGD-modified stably transfected engineered immune cells at an MOI of 5-50.
[0013] Further, in step (1), step 1 stably expressed the arginine-glycine-aspartic acid (RGD) peptide on the macrophage membrane by a lentiviral method. Similar to the construction of CAR-M cells, macrophages were transduced with a lentiviral vector with a CAR-like structure: the RGD coding sequence was preceded by a CD8 signal peptide, followed by a CD8α hinge and transmembrane domain, and a myc-tag protein was connected near the end of the CD8 signal peptide. Monocytes / macrophages with good growth conditions were inoculated in a 6-well plate, and then the packaged lentivirus was added at an MOI of 5-50. After 24-72 hours of viral infection, stable transfected cells were obtained by screening using fluorescent markers (green fluorescence GFP) or eukaryotic antibiotic resistance (puromycin 1-6μg / mL).
[0014] Step 2: Co-culture the prepared engineered cells stably transfected with RGD peptide with VNP20009 or its genetically modified strains: 1-100×10 5 VNP20009 or its genetically modified monoclonal strain was picked from the agar plate and activated overnight in LB liquid medium. The bacterial solution cultured to the logarithmic growth phase was centrifuged at 5000-8000 rpm for 5-10 min, the supernatant was discarded and the precipitate was resuspended in sterile physiological saline. After adjusting the OD600 to 0.6-1.2, the bacteria were added to the 6-well plate containing the above cells (MOI 1-100) and co-cultured for different time periods.
[0015] Step 3: After staining the cell nucleus with Hoechst (Solarbio, C0030, Beijing, China), observe the morphological changes of the cells under a microscope; record the changes in the percentage of the above-mentioned monocyte / macrophage fragmentation at different time points of co-culture of cells and bacteria; after different time points, discard the supernatant, wash with sterile PBS 2-3 times, and then incubate with cell culture medium supplemented with 50-125μg / ml gentamicin for 20-60min to kill the extracellular strain. Discard the supernatant and wash with sterile PBS 2-3 times; collect the cells to obtain the above-mentioned live RGD-modified monocytes / macrophages (abbreviated as GEM / VNP) loaded with VNP20009 or its genetically modified strains;
[0016] Step 4: In order to detect the number of VNP20009 or its genetically modified strains effectively loaded in RGD-modified monocytes / macrophages, a cell counter was used to detect the number of live cells of monocytes / macrophages loaded with attenuated Salmonella at different time points, and then the cells were lysed with 0.5% Triton X-100 at room temperature; the lysate was diluted in multiple ratios, applied to LB agar plates supplemented with kanamycin, and incubated at 37°C overnight; the number of live bacteria loaded in RGD-modified monocytes / macrophages was counted.
[0017] Further, in step (step 1), taking the macrophage cell line RAW264.7 as an example, the RGD-packaged lentivirus and macrophages were incubated at an MOI of 15 for 24 hours, and puromycin was incubated / screened at 4 μg / mL as the optimal conditions. The RGD-modified macrophages prepared under this condition can stably detect RGD on the cell membrane surface. Compared with unmodified macrophages, the adhesion of RGD-modified macrophages to various tumor cells (mouse breast cancer cells, melanoma cells, and colorectal cancer cells) was increased by 1.8-2.4 times; specifically, taking the macrophage cell line RAW264.7 as an example: engineered macrophages (R-GEM cells) expressing RGD peptides on the outer membrane surface were generated by lentiviral infection. Anti-tumor attenuated Salmonella typhimurium VNP20009 or its genetically modified strains are encapsulated in these macrophages to form R-GEM / VNP cells. The bacteria in the cells can survive for a long time and achieve delayed release. Subsequently, the engineered macrophages and other immune cells were prepared and loaded with anti-tumor bacteria (including attenuated Salmonella, Listeria, BCG, etc.) in vitro, and their combined use was used to treat tumors.
[0018] Furthermore, in step (step 2), after comprehensively considering the strain loading amount and cell integrity, the co-culture time of 60 minutes was selected as the optimal time point for preparing live monocytes / macrophages loaded with VNP20009 or its genetically modified strains. At this time, the load of live bacteria in the cells was high, with a load of approximately 294 strains per 100 cells, and the cell integrity was >90%.
[0019] Furthermore, in step (2), the attenuated Salmonella typhimurium is attenuated Salmonella typhimurium VNP20009 and its genetically modified strains; RGD peptide-modified stably transfected engineered immune cells are obtained by fluorescent labeling or eukaryotic antibiotic resistance screening, and the cells are co-incubated with the attenuated Salmonella strain VNP20009 or its genetically modified strains, and gentamicin is used to eliminate the extracellular free strains to obtain RGD peptide-modified engineered monocytes or macrophages loaded with the VNP20009 strain.
[0020] The invention discloses an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella, wherein the engineered monocyte or macrophage is obtained by a preparation method.
[0021] The invention discloses an application of an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella in the preparation of an anti-tumor drug.
[0022] Furthermore, the therapeutic dose of engineered monocytes or macrophages loaded with attenuated Salmonella modified with RGD peptide was 0.4-40×10 5 cells / mouse, corresponding to the actual amount of attenuated Salmonella is 0.1-10×10 6 CFU / mouse; single administration.
[0023] Furthermore, the anti-tumor drug includes at least one of an intravenous injection preparation, an intratumor injection preparation or an intraperitoneal injection preparation.
[0024] The invention discloses a combined application of the engineered monocytes or macrophages loaded with attenuated Salmonella and RGD peptide modified with other conventional anti-tumor drugs or methods.
[0025] Beneficial effects: The preparation method of the RGD peptide-modified immune cells loaded with attenuated Salmonella of the present invention is simple and easy to operate, and has a good application prospect. The RGD peptide modification strategy improves the targeted enrichment performance of immune cells for micro-tumor foci or metastatic foci; cell camouflage avoids the large-scale exposure of bacterial heterologous stimuli in vivo, and improves the biosafety of bacterial-based anti-tumor therapy. The high titer of intratumoral strains also promotes anti-tumor immune response, thereby obtaining stronger and more lasting anti-tumor efficacy.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] (1) RGD peptide modification of monocytes or macrophages improves the recognition and adhesion of cells to tumor cells, while having almost no effect on their original chemotaxis to the tumor area and foreign body phagocytosis (such as attenuated Salmonella). The facultative anaerobic bacteria Salmonella typhimurium VNP20009 or its genetically modified strain was selected because it can survive for a long time in immune cells such as monocytes / macrophages, and the strain itself has good tumor colonization and tumor inhibition effects.
[0028] (2) Use lentivirus to modify and transform the genome of monocytes or macrophages to obtain engineered cells that can stably and persistently express RGD peptides. The specific recognition and adhesion of RGD peptides to tumor cells have been widely recognized and have been successfully used in clinical tumor tracing and treatment. The applicability and safety of this strategy are ensured. RGD peptide modification gives immune cells more efficient enrichment performance in tumor tissues. Unlike traditional chemical addition RGD modification methods, genome-based membrane modification minimizes irreversible damage to cells and retains normal protein sites on the cell membrane.
[0029] (3) The method for preparing monocytes or macrophages modified with RGD peptides based on lentiviral packaging of the present invention can achieve rapid acquisition and preparation of such engineered cells, and the cells are non-pathogenic, and attenuated Salmonella VNP20009 or its genetically modified strains are low-toxic and easy-to-culture bacteria with low cost, so the present invention has the prospect of large-scale promotion and application. RGD peptide-modified monocytes or macrophages loaded with attenuated Salmonella VNP20009 or its genetically modified strains not only verified its significantly improved biosafety compared with the use of a single strain in a mouse model, but also demonstrated a significantly improved anti-tumor effect compared with a single cell.
[0030] (4) After administration, RGD peptide-modified monocytes / macrophages loaded with attenuated Salmonella can be efficiently enriched inside the tumor, preventing the bacteria from being delivered to normal organs. The encapsulation and camouflage of monocytes / macrophages also effectively prevents premature exposure of bacteria. Ultimately, it indirectly inhibits tumors by releasing intracellular strains to activate / regulate the immune system. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0032] FIG1 is a diagram showing the preparation and evaluation of engineered macrophages modified with the RGD peptide of the present invention.
[0033] Figure 1A The present invention is a schematic diagram of the process of preparing RGD peptide-modified engineered macrophages (R-GEM) based on lentiviral packaging.
[0034] Figure 1B The schematic diagram of the preparation of engineered macrophages (R-GEM) modified with RGD peptide obtained in the present invention is shown in FIG. RGD peptide (Arg-Gly-Asp) is spontaneously produced by the cells on the outer membrane surface of macrophages.
[0035] Figure 1C Fluorescence images of engineered macrophages modified with RGD peptides of the present invention (R-GEM) are prepared. Including: fluorescence images of blank modified genetically engineered macrophages (B-GEM) and genetically engineered macrophages modified with RGD peptides (R-GEM). RGD polypeptide (red) is expressed on the extracellular surface of macrophages (green). Hoechst dye marks the nucleus (blue). Scale bar = 10 μm. 1 represents B-GEM cells, 2 represents R-GEM cells.
[0036] Figure 1D The present invention compares the adhesion effect of B-GEM cells and R-GEM cells labeled with cell membrane red dye DiI on 4T1 breast cancer tumor cells (left), B16F10 melanoma tumor cells (middle) and MC38 colorectal cancer tumor cells (right). Correspondingly, representative fluorescent images of two types of macrophages adhering to tumor cells after 10 minutes of co-incubation are shown (red arrows point to macrophages attached to tumor cells). And quantitative dot plots of two types of macrophages adhering to cells after coexisting with 4T1 cells for 10 seconds or 10 minutes (n=5). Scale bar=100μm. ns=not significant, **P<0.01, ***P<0.001. 1 represents B-GEM cells and 2 represents R-GEM cells.
[0037] Figure 1E The present invention is a comparative bar graph of the adhesion of B-GEM and R-GEM cells to 4T1 tumor cells after culturing tumor cells in a culture medium pre-added with exogenous free RGD peptide (0-8 μM) for 10 minutes. Exogenous free RGD peptide can dose-dependently reverse the adhesion between R-GEM cells and tumor cells (n=5). ns=not significant, *P<0.05, **P<0.01, ***P<0.001. 1 represents B-GEM cells, 2 represents R-GEM cells.
[0038] Figure 1F This is a transwell chemotaxis test of the R-GEM cells of the present invention for the chemokine CCL2 (indirect co-culture with 2ng / mL CCL2 in a Transwell chamber with a pore size of 8μm for 12 hours). The figure shows a representative picture of macrophages that have completed chemotaxis (left), and a quantitative comparison of the chemotactic effect of R-GEM cells with or without CCL2 added to the lower chamber (right) (n=5). The black arrow points to the chemotactic macrophage. Scale bar = 100μm. ****P<0.0001. 1 represents the addition of BSA (bovine serum albumin) to the lower chamber, and 2 represents the addition of chemokine CCL2 to the lower chamber. R-GEM cells were added to both the upper chambers 1 and 2.
[0039] Figure 1GQuantitative comparison of the accumulation of different macrophages in the lungs 2 hours after intravenous injection of B-GEM cells or R-GEM cells labeled with cell membrane near-infrared dye DiR in the 4T1 tumor cell metastasis mouse model of the present invention (left) (n=5), and representative organ live imaging images of mice in different groups (right). *P<0.05. 1 represents B-GEM cells, and 2 represents R-GEM cells.
[0040] Figure 1H This is a fluorescence photograph of frozen sections of lung tissue 2 hours after intravenous injection of B-GEM or R-GEM cells labeled with cell membrane near-infrared dye DiI in the 4T1 tumor cell metastasis mouse model of the present invention. 4T1-GFP tumor cells (green) were used. The red arrow points to the DiI-labeled GEM cells in the tumor tissue. DAPI marks the cell nucleus (blue). Scale bar = 40μm. 1 represents B-GEM cells and 2 represents R-GEM cells.
[0041] FIG. 2 shows the preparation and evaluation of engineered macrophages modified with RGD peptide and loaded with attenuated Salmonella of the present invention.
[0042] Figure 2A Schematic diagram of the preparation of engineered macrophages loaded with anticancer bacteria intracellularly while modified with RGD peptide in the present invention. VNP20009 or its genetically modified strain (abbreviated as VNP) is co-incubated with R-GEM cells to obtain R-GEM cells loaded with VNP20009 or its genetically modified strain (abbreviated as R-GEM / VNP). VNP20009 or its genetically modified strain can survive and proliferate in R-GEM cells, and achieve delayed release while R-GEM cells undergo oncosis / rupture.
[0043] Figure 2B The figure is a comparison of the number of active strains and macrophage activity in R-GEM cells after the R-GEM cells of the present invention were co-cultured with VNP20009 or its genetically modified strains for different time periods (30 / 60 / 90 / 120 minutes, MOI 10) (n=3).
[0044] Figure 2C It is a representative fluorescent image of R-GEM cells and R-GEM / VNP cells of the present invention. R-GEM / VNP cells are obtained by co-culturing R-GEM cells and VNP strains at MOI 10 for 60 minutes. Green represents macrophage cytoskeleton actin (Actin), DAPI (blue) stains the nucleus, and red is VNP-RFP strain. The red arrow points to the R-GEM cells (R-GEM / VNP cells) that are successfully loaded with VNP strains. Scale bar = 25μm. 1 represents R-GEM cells, and 2 represents R-GEM / VNP cells.
[0045] Figure 2D Representative transmission electron micrographs of R-GEM / VNP cells (MOI 10, co-cultured for 60 minutes) of the present invention. The red arrows in the magnified images point to the VNPs or their genetically modified strains in the cells. Scale bar = 2 μm (left) or 300 nm (right).
[0046] Figure 2E The figure shows the change in the number of surviving bacteria in the R-GEM / VNP cells of the present invention after being cultured in a medium supplemented with 50 μg / ml gentamicin for different time periods (0, 3, 6, 12, 24 h) (left) (n=3). And the representative fluorescence micrographs of intracellular bacteria in the R-GEM / VNP cells after continuous culture for 0 / 12 hours (right). The arrows point to intracellular bacteria. Scale bar=10 μm.
[0047] FIG. 3 is a graph showing the biological activity evaluation of the engineered macrophage intracellular strain loaded with attenuated Salmonella and modified with the RGD peptide of the present invention.
[0048] Figure 3A Schematic diagram of activation of the psifB-RFP-VNP strain of the present invention. The psifB-RFP-VNP strain cannot be activated outside the cell. Therefore, if the activated psifB-RFP-VNP strain expressing RFP is also observed outside the prepared R-GEM / psifB-RFP-VNP cells, it indicates that the bacteria in the cell have been successfully released.
[0049] Figure 3B Representative images of delayed release of psifB-RFP-VNP strains in R-GEM / psifB-RFP-VNP cells of the present invention. Intracellular bacteria are activated and produce red fluorescence. R-GEM / psifB-RFP-VNP cells were observed to rupture (no longer having a clear membrane structure), and activated psifB-RFP-VNP bacteria were observed at the rupture outlet (cultured for 120 minutes). The red arrow points to the activated bacteria inside the cell, and the green arrow points to the activated bacteria outside the cell. Scale bar = 10 μm. 1 represents the image of 0 minutes of culture, and 2 represents the image of 120 minutes of culture.
[0050] Figure 3CThe release curves of strains in R-GEM / VNP cells cultured in medium with or without gentamicin (0.5 μg / mL) of the present invention (n=4). In ordinary medium (without gentamicin), the released strains can proliferate rapidly, simulating the release in an environment conducive to growth such as tumors. On the contrary, in a medium with gentamicin (0.5 μg / mL), the proliferation ability of the released strains is inhibited, simulating the release in an unfavorable environment where it is difficult to grow, such as in healthy tissues with a strong immune response. 1 represents the addition of gentamicin, and 2 represents the absence of gentamicin.
[0051] Figure 3D Comparison of the growth curves of the normal VNP strain (VNP-N) of the present invention and the VNP strain released by cells (VNP-R) in liquid LB medium (n=3). ns=not significant. 1 represents the VNP-N strain, and 2 represents the VNP-R strain.
[0052] Figure 3E The changes in the mRNA levels of M1 macrophage markers after the VNP-R strain or VNP-N strain of the present invention was co-cultured with M0 macrophages in vitro for 6 hours (MOI 10) (n = 3). ns = not significant. 0 represents saline treatment, 1 represents VNP-N strain treatment, and 2 represents VNP-R strain treatment.
[0053] Figure 3F Quantitative changes in the proportion of dead cells (PI+) after 12 hours of co-culture of VNP-R or VNP-N with 4T1-GFP cells by flow cytometry analysis of the present invention (n=3). ns=not significant. 0 represents saline treatment, 1 represents VNP-N strain treatment, and 2 represents VNP-R strain treatment.
[0054] FIG. 4 is a graph showing the evaluation of the biological activity of engineered macrophages loaded with attenuated Salmonella modified with the RGD peptide of the present invention.
[0055] Figure 4A Comparison of the macrophage polarization phenotypes of R-GEM and R-GEM / VNP cells in the present invention. The mRNA levels of M1 macrophage-related marker genes (including IL23α, IL1β, IL6, etc.) were detected by qPCR. The levels of reactive oxygen species (ROS) and nitric oxide (NO) in macrophages were detected by flow cytometry (n=4). * indicates a significant difference. 1 represents R-GEM cells, and 2 represents R-GEM / VNP cells.
[0056] Figure 4BThe schematic diagram of the indirect co-culture of R-GEM / VNP cells and 4T1-GFP tumor cells of the present invention. R-GEM / VNP cells were added to a 0.4 μm perforated culture dish, which allowed small molecules such as cytokines to pass freely, but cells or bacteria could not pass through. PI (propidium iodide) staining was used to mark dead tumor cells.
[0057] Figure 4C Comparison of the green fluorescence intensity (left) and red fluorescence intensity (right) of the lower tumor cells after co-culture of R-GEM or R-GEM / VNP cells with 4T1-GFP cells in 4B of the present invention for 18 hours (n=5). The green fluorescence intensity decreases with the increase of cell number and activity, and the red fluorescence intensity is positively correlated with the number of dead cells. The upper chamber without added cells served as a blank control. *P<0.05, **P<0.01, ***P<0.001. 1 represents saline treatment, 2 represents R-GEM cell treatment, and 3 represents R-GEM / VNP cell treatment.
[0058] Figure 4D Comparison of the phagocytosis of fluorescent microspheres by R-GEM cells or R-GEM / VNP cells of the present invention after co-culture with fluorescent microspheres for 0 / 1 / 3 / 6h (MOI10) (based on the mean fluorescence intensity detection by flow cytometry) (n=4). ns=not significant. **P<0.01, ***P<0.001. 1 represents R-GEM cells, 2 represents R-GEM / VNP cells.
[0059] Figure 4E This is a transwell chemotaxis test of the R-GEM cells and R-GEM / VNP cells of the present invention for the chemokine CCL2 (indirect co-culture with 2 ng / mL CCL2 in a Transwell chamber with a pore size of 8 μm for 12 hours) (n=6). *P<0.05. 1 represents R-GEM cells, and 2 represents R-GEM / VNP cells.
[0060] FIG. 5 is an evaluation of the in vivo delivery efficiency of engineered macrophages loaded with attenuated Salmonella modified with the RGD peptide of the present invention.
[0061] Figure 5AThe present invention shows the changes in bacterial density and bioluminescence in lung tissue (left) and normal organs (including heart, liver, spleen and kidney) (right) 3 / 12 / 72 hours after intravenous injection of a single VNP strain or B-GEM / VNP cells or R-GEM / VNP cells or R-GEM+VNP mixed cells in the 4T1 tumor cell lung metastasis mouse model (n=3 or 4). The strain used above is the VNP-LuxCDABE strain (which can spontaneously generate bioluminescence). ns=not significant. *P<0.05, **P<0.01, ***P<0.001. 1 represents a single VNP strain, 2 represents B-GEM / VNP cells, 3 represents R-GEM / VNP cells, and 4 represents R-GEM+VNP mixed cells.
[0062] Figure 5B Schematic diagram of the R-GEM / VNP cells of the present invention protecting intracellular bacteria from rapid clearance by activated neutrophils (above). Changes in the number of active bacterial strains in the culture medium after co-culture of activated neutrophils with R-GEM / VNP cells or R-GEM+VNP for different time periods (0 / 30 / 60 / 90 minutes) (n=3). ns=not significant. *P<0.05, ****P<0.0001. 1 represents R-GEM+VNP mixed cells, and 2 represents R-GEM / VNP cells.
[0063] Figure 5C The near-infrared light intensity of macrophages in the lungs of mice with 4T1 cell lung metastasis model of the present invention after injection of R-GEM+VNP or R-GEM / VNP cells labeled with cell membrane near-infrared dye DiR (n=4) 1 / 2 / 4 / 8 / 16 hours later. The strain used above is the VNP-LuxCDABE strain (which can spontaneously generate bioluminescence). 1 represents R-GEM / VNP cells, and 2 represents R-GEM+VNP mixed cells.
[0064] Figure 5D The bacterial density and bioluminescence intensity in the lungs of 4T1 cell lung metastasis model mice injected with R-GEM+VNP or R-GEM / VNP cells labeled with cell membrane near-infrared dye DiR (n=4) 1 / 2 / 4 / 8 / 16 hours later. The strain used is the VNP-LuxCDABE strain (which can spontaneously generate bioluminescence). 1 represents R-GEM / VNP cells, and 2 represents R-GEM+VNP mixed cells.
[0065] Figure 5EThe distribution of VNP strains in lung metastatic lesions 12 hours after injection of R-GEM / VNP cells of the present invention. The diagram shows an enlarged view of healthy lung tissue (in the blue dotted box) and tumor tissue (in the red dotted box). Green is the 4T1-GFP tumor cells used (expressing green fluorescent protein), DAPI (blue) staining the nucleus, and red is the VNP-RFP strain. The red arrow points to the VNP strain in the tumor tissue. Scale bar = 40μm.
[0066] Fig. 5F In the present invention, in the 4T1 cell lung metastasis model mice, R-GEM / VNP cells or VNP strains were resuspended in saline supplemented with gentamicin (600 μg / 100 μL), and then intravenously injected into tumor-bearing mice. After 1 / 2 / 4 hours, the bacterial titer in one metastasis was analyzed by plating conversion (n=3). 1 represents R-GEM / VNP cells, and 2 represents a single VNP strain.
[0067] Figure 5G In the present invention, in a 4T1 cell lung metastasis model mouse, the bacterial bioluminescence intensity changes in the lungs of tumor-bearing mice at different time points after intravenous injection of R-GEM / VNP cells were compared. The strain used above was the VNP-LuxCDABE strain (which can spontaneously generate bioluminescence). The bacterial density in the tumor increased within 120 hours and then decreased. The strain can exist in the tumor for more than 18 days (n=4).
[0068] FIG. 6 is an in vivo safety evaluation of the engineered macrophages loaded with attenuated Salmonella modified with the RGD peptide of the present invention.
[0069] Fig. 6A This is a macroscopic comparison of the liver status of mice in different groups one day after intravenous injection of saline, a single VNP strain, R-GEM / VNP cells or a simple mixture of R-GEM and VNP strains (R-GEM+VNP) in the 4T1 cell lung metastasis model mice of the present invention. Representative pictures of the livers of mice in each group (black arrows point to the lesion area, left), and statistical comparison of the number of liver lesions (right) (n=5). Scale bar=10μm. ns=not significant. **P<0.01. 1 represents saline treatment, 2 represents single VNP strain treatment, 3 represents R-GEM / VNP cell treatment, and 4 represents R-GEM+VNP mixed cell treatment.
[0070] Figure 6BThe present invention is a microscopic comparison of the liver status of different groups of mice in the 4T1 cell lung metastasis model mouse, intravenous injection of normal saline, a single VNP strain, R-GEM / VNP cells or a simple mixture of R-GEM and VNP strains (R-GEM+VNP) one day after. Representative H&E images of the liver of mice in each group (white dotted lines indicate severe injury sites, left), and comparison of mouse serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (right) (n=5). Scale bar = 10 μm. ns = not significant. ****P<0.0001. 1 represents normal saline treatment, 2 represents single VNP strain treatment, 3 represents R-GEM / VNP cell treatment, and 4 represents R-GEM+VNP mixed cell treatment.
[0071] Figure 6C Comparison of spleen weights of mice in different groups after intravenous injection of saline, single VNP strain, R-GEM / VNP cells or a simple mixture of R-GEM and VNP strains (R-GEM+VNP) in 4T1 cell lung metastasis model mice (n=5) 1 day. ns=not significant. **P<0.01. 1 represents saline treatment, 2 represents single VNP strain treatment, 3 represents R-GEM / VNP cell treatment, and 4 represents R-GEM+VNP mixed cell treatment.
[0072] Fig.6D Representative H&E images of the heart, spleen and kidney of different groups of mice in the 4T1 cell lung metastasis model mouse of the present invention, one day after intravenous injection of saline, a single VNP strain, R-GEM / VNP cells or a simple mixture of R-GEM and VNP strains (R-GEM+VNP). Scale bar = 40 μm. 1 represents saline treatment, 2 represents single VNP strain treatment, 3 represents R-GEM / VNP cell treatment, and 4 represents R-GEM+VNP mixed cell treatment.
[0073] Fig. 6E The present invention is a comparison of the weight changes of mice in different groups after intravenous injection of normal saline, a single VNP strain, R-GEM / VNP cells or a simple mixture of R-GEM and VNP strains (R-GEM+VNP) in 4T1 cell lung metastasis model mice (n=5). 1 represents normal saline treatment, 2 represents single VNP strain treatment, 3 represents R-GEM / VNP cell treatment, and 4 represents R-GEM+VNP mixed cell treatment.
[0074] FIG. 7 is an evaluation of the anti-tumor effect of engineered macrophages loaded with attenuated Salmonella modified with the RGD peptide of the present invention.
[0075] Fig. 7A Different groups of the present invention (including physiological saline, R-GEM cells (2×10 per mouse)5 cells), single VNP strain (5×10 per mouse 5 CFU), R-GEM+VNP (2×10 per mouse 5 cells and 5×10 5 CFU) and R-GEM / VNP cells (2×10 per mouse 5 Schematic diagram of the treatment process of 4T1 lung metastatic tumor model using 4T1 cells.
[0076] Figure 7B Representative lung photos of mice in each group after 12 days of treatment in different ways in the 4T1 cell lung metastasis model mice of the present invention (above), and corresponding representative HE staining images of the lungs (below). Scale bar = 200 μm. Black arrows point to lung tumor metastases. 1 represents saline treatment, 2 represents R-GEM cell treatment, 3 represents single VNP strain treatment, 4 represents R-GEM+VNP mixed cell treatment, and 5 represents R-GEM / VNP cell treatment.
[0077] Figure 7C Comparison of lung weights of mice in each group after 12 days of treatment with different methods in the 4T1 cell lung metastasis model mice (upper), and comparison of the number of lung tumor metastases (lower) (n=6) (n=6). ns=not significant. **P<0.01, ***P<0.001. 1 represents saline treatment, 2 represents R-GEM cell treatment, 3 represents single VNP strain treatment, 4 represents R-GEM+VNP mixed cell treatment, and 5 represents R-GEM / VNP cell treatment.
[0078] Fig.7D This is a comparison of the survival curves of mice in each group after different treatments in the 4T1 cell lung metastasis model mice of the present invention (n=6). The mice were euthanized when they reached the humane endpoint. **P<0.01. 1 represents saline treatment, 2 represents R-GEM cell treatment, and 3 represents R-GEM / VNP cell treatment. DETAILED DESCRIPTION
[0079] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.
[0080] The following examples are provided to help further understand the present invention, but the present invention is not limited thereto.
[0081] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0082] The first aspect of the present invention is to provide a method for preparing an engineered monocyte or macrophage loaded with attenuated Salmonella modified with RGD peptide, comprising the following steps:
[0083] (1) using lentiviral transduction technology to package, infect, and screen the virus to transform wild-type monocytes or macrophages into genetically engineered cells that can express RGD peptides on the cell outer membrane surface;
[0084] (2) co-culturing the genetically engineered cells with attenuated Salmonella typhimurium at a MOI ratio of 1-100 for 20-120 minutes to obtain RGD-modified engineered cells loaded with attenuated Salmonella.
[0085] In some embodiments, in step (1), the monocyte / macrophage cell lines used for RGD peptide modification and intracellular strain loading include but are not limited to any one of THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, RAW264.7, J774.1, Ana-1, iBMDM, U937, and mouse / human primary monocytes / macrophages.
[0086] In some embodiments, in step (1), the monocytes are any one of the monocytic cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, and primary monocytes derived from bone marrow, peripheral blood or stem cells, and the macrophages are any one of the macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, and primary monocytes derived from bone marrow, peripheral blood, peritoneal cavity or stem cells.
[0087] In some embodiments, in step (1), the RGD peptide is arginine-glycine-aspartic acid, which can specifically bind to the αvβ3 receptor highly expressed in tumor cells; the lentiviral solution prepared by packaging with 293T / 293FT cells is co-incubated with monocytes or macrophages to prepare RGD-modified stably engineered immune cells at an MOI of 5-50.
[0088] In some embodiments, in step (2), the attenuated Salmonella typhimurium is attenuated Salmonella typhimurium VNP20009 and its genetically modified strains; fluorescent labeling or eukaryotic antibiotic resistance screening is used to obtain RGD peptide-modified stably engineered immune cells, and the cells are co-incubated with attenuated Salmonella VNP20009 or its genetically modified strains, and gentamicin is used to eliminate extracellular free strains to obtain RGD peptide-modified engineered monocytes or macrophages loaded with VNP20009 strains.
[0089] The second aspect of the present invention provides an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella, wherein the engineered monocyte or macrophage is obtained by a preparation method.
[0090] The third aspect of the present invention provides the use of an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella in the preparation of an anti-tumor drug.
[0091] In some embodiments, the therapeutic dose of engineered monocytes or macrophages loaded with attenuated Salmonella modified with RGD peptide is 0.4-40×10 5 cells / mouse, corresponding to the actual amount of attenuated Salmonella is 0.1-10×10 6 CFU / mouse; single administration.
[0092] In some embodiments, the anti-tumor drug comprises at least one of an intravenous injection formulation, an intratumor injection formulation, or an intraperitoneal injection formulation.
[0093] The fourth aspect of the present invention provides a combined use of an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella and other conventional anti-tumor drugs or methods.
[0094] Example 1
[0095] The first aspect of the present invention is to provide a method for preparing an engineered monocyte or macrophage loaded with attenuated Salmonella modified with RGD peptide, comprising the following steps:
[0096] (1) using lentiviral transduction technology to package, infect, and screen the virus to transform wild-type monocytes or macrophages into genetically engineered cells that can express RGD peptides on the cell outer membrane surface;
[0097] (2) co-culturing the genetically engineered cells with attenuated Salmonella typhimurium at a MOI ratio of 1-100 for 20-120 minutes to obtain RGD-modified engineered cells loaded with attenuated Salmonella.
[0098] The attenuated Salmonella typhimurium is attenuated Salmonella typhimurium VNP20009 and its genetically modified strains; RGD peptide-modified stably engineered immune cells are obtained by fluorescent labeling or eukaryotic antibiotic resistance screening, and the cells are co-incubated with attenuated Salmonella VNP20009 or its genetically modified strains, and extracellular free strains are eliminated by gentamicin to obtain RGD peptide-modified engineered monocytes or macrophages loaded with VNP20009 strains.
[0099] Example 2
[0100] The difference between Example 2 and Example 1 is that the method for preparing an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella of the present invention comprises the following steps:
[0101] In step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells that can express the RGD peptide on the cell outer membrane surface;
[0102] Step 1 stably expressed the arginine-glycine-aspartic acid (RGD) peptide on the macrophage membrane by the lentiviral method. Similar to the construction of CAR-M cells, macrophages were transduced with a lentiviral vector with a CAR-like structure: the RGD coding sequence was preceded by a CD8 signal peptide, followed by a CD8α hinge and transmembrane domain, and a myc-tag protein was connected near the end of the CD8 signal peptide. Monocytes / macrophages with good growth conditions were inoculated in a 6-well plate, and then the packaged and prepared lentivirus was added at an MOI of 5-50. After 24-72 hours of viral infection, stable transfected cells were obtained by screening using fluorescent markers (green fluorescent GFP) or eukaryotic antibiotic resistance (puromycin 1-6μg / mL).
[0103] Step 2: Co-culture the prepared engineered cells stably transfected with RGD peptide with VNP20009 or its genetically modified strains: 1-100×10 5 VNP20009 or its genetically modified monoclonal strain was picked from the agar plate and activated overnight in LB liquid medium. The bacterial solution cultured to the logarithmic growth phase was centrifuged at 5000-8000 rpm for 5-10 min, the supernatant was discarded and the precipitate was resuspended in sterile physiological saline. After adjusting the OD600 to 0.6-1.2, the bacteria were added to the 6-well plate containing the above cells (MOI 1-100) and co-cultured for different time periods.
[0104] Step 3: After staining the cell nucleus with Hoechst (Solarbio, C0030, Beijing, China), observe the morphological changes of the cells under a microscope; record the changes in the percentage of the above-mentioned monocyte / macrophage fragmentation at different time points of co-culture of cells and bacteria; after different time points, discard the supernatant, wash with sterile PBS 2-3 times, and then incubate with cell culture medium supplemented with 50-125μg / ml gentamicin for 20-60min to kill the extracellular strain. Discard the supernatant and wash with sterile PBS 2-3 times; collect the cells to obtain the above-mentioned live RGD-modified monocytes / macrophages (abbreviated as GEM / VNP) loaded with VNP20009 or its genetically modified strains;
[0105] Step 4: In order to detect the number of VNP20009 or its genetically modified strains effectively loaded in RGD-modified monocytes / macrophages, a cell counter was used to detect the number of live cells of monocytes / macrophages loaded with attenuated Salmonella at different time points, and then the cells were lysed with 0.5% Triton X-100 at room temperature; the lysate was diluted in multiple ratios, applied to LB agar plates supplemented with kanamycin, and incubated at 37°C overnight; the number of live bacteria loaded in RGD-modified monocytes / macrophages was counted.
[0106] Example 3
[0107] The difference between Example 3 and Example 2 is that: in step 1 of step (1), taking the macrophage cell line RAW264.7 as an example, the RGD-packaged lentivirus and macrophages are incubated at an MOI of 15 for 24 hours, and the puromycin is incubated / screened at 4 μg / mL as the optimal condition. The RGD-modified macrophages prepared under this condition can stably detect RGD on the cell membrane surface. Compared with unmodified macrophages, the adhesion of RGD-modified macrophages to various tumor cells (mouse breast cancer cells, melanoma cells, colorectal cancer cells) is increased by 1.8-2.4 times; specifically, taking the macrophage cell line RAW264.7 as an example: engineered macrophages (R-GEM cells) expressing RGD peptides on the outer membrane surface are generated by lentiviral infection. Anti-tumor attenuated Salmonella typhimurium VNP20009 or its genetically modified strain is encapsulated in these macrophages, thereby forming R-GEM / VNP cells. The bacteria in the cells can survive for a long time and achieve delayed release. Subsequently, the engineered macrophages and other immune cells were prepared and loaded with anti-tumor bacteria (including attenuated Salmonella, Listeria, BCG, etc.) in vitro, and their combined use was used to treat tumors.
[0108] In step 2, after comprehensively considering the strain loading amount and cell integrity, a co-culture time of 60 minutes was selected as the optimal time point for preparing live monocytes / macrophages loaded with VNP20009 or its genetically modified strains. At this time, the load of live bacteria in the cells was high, with a load of approximately 294 strains per 100 cells, and the cell integrity was >90%.
[0109] Example 4
[0110] The difference between Example 4 and Example 1 is that:
[0111] The method for preparing an RGD peptide-modified engineered monocyte or macrophage loaded with attenuated Salmonella of the present invention comprises the following steps:
[0112] In step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is THP1.
[0113] Example 5
[0114] The difference between Example 5 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading includes iBMMC.
[0115] Example 6
[0116] The difference between Example 6 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is J-111.
[0117] Example 7
[0118] The difference between Example 7 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is Mono-Mac-1.
[0119] Example 8
[0120] The difference between Example 8 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is JOSK-M.
[0121] Example 9
[0122] The difference between Example 9 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is RAW264.7.
[0123] Example 10
[0124] The difference between Example 10 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is J774.1.
[0125] Embodiment 11
[0126] The difference between Example 11 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is Ana-1.
[0127] Example 12
[0128] The difference between Example 12 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is iBMDM.
[0129] Embodiment 13
[0130] The difference between Example 13 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is U937.
[0131] Embodiment 14
[0132] The difference between Example 14 and Example 1 is that: in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is primary mouse monocytes.
[0133] Embodiment 15
[0134] The difference between Example 15 and Example 1 is that in step (1), the virus is packaged, infected, and screened using lentiviral transduction technology to transform wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is human primary monocytes.
[0135] Example 16
[0136] The difference between Example 16 and Example 15 is that the monocytes are monocytic cell line THP1.
[0137] Embodiment 17
[0138] The difference between Example 17 and Example 15 is that the monocytes are monocyte cell line iBMMC.
[0139] Embodiment 18
[0140] The difference between Example 18 and Example 15 is that the monocytes are monocytic cell line J-111.
[0141] Embodiment 19
[0142] The difference between Example 19 and Example 15 is that the monocytes are monocytic cell line Mono-Mac-1.
[0143] Embodiment 20
[0144] The difference between Example 20 and Example 15 is that the monocytes are monocyte cell line JOSK-M.
[0145] Embodiment 21
[0146] The difference between Example 21 and Example 15 is that the monocytes are primary monocytes of bone marrow.
[0147] Embodiment 22
[0148] The difference between Example 22 and Example 15 is that the monocytes are primary monocytes from peripheral blood.
[0149] Embodiment 23
[0150] The difference between Example 23 and Example 15 is that the monocytes are primary monocytes derived from stem cells.
[0151] Embodiment 24
[0152] The difference between Example 24 and Example 1 is that: in step (1), the lentiviral transduction technology is used to package, infect, and screen the virus to transform the wild-type monocytes or macrophages into genetically engineered cells capable of expressing RGD peptide on the cell outer membrane surface; the monocyte cell line / macrophage cell line used for RGD peptide modification and intracellular strain loading is mouse / human primary macrophages.
[0153] Embodiment 25
[0154] The difference between Example 25 and Example 24 is that:
[0155] The macrophages are macrophage cell line RAW264.7. The RGD peptide is arginine-glycine-aspartic acid, which can specifically bind to the αvβ3 receptor highly expressed in tumor cells; the lentiviral solution prepared by packaging with 293T / 293FT cells is co-incubated with monocytes or macrophages to prepare RGD-modified stable engineered immune cells at an MOI of 5-50.
[0156] Embodiment 26
[0157] The difference between Example 26 and Example 24 is that:
[0158] The macrophages are macrophage cell line J774.1.
[0159] Embodiment 27
[0160] The difference between Example 27 and Example 24 is that:
[0161] The macrophages are macrophage cell line Ana-1.
[0162] Embodiment 28
[0163] The difference between Example 28 and Example 24 is that:
[0164] The macrophages are iBMDM macrophages.
[0165] Embodiment 29
[0166] The difference between Example 29 and Example 24 is that:
[0167] The macrophages are macrophage cell line U937.
[0168] Embodiment 30
[0169] The difference between Example 30 and Example 24 is that:
[0170] The macrophages are primary monocytes from the bone marrow.
[0171] Embodiment 31
[0172] The difference between Example 31 and Example 24 is that:
[0173] The macrophages are primary monocytes from peripheral blood.
[0174] Embodiment 32
[0175] The difference between Example 32 and Example 24 is that:
[0176] The macrophages are primary monocytes from the peritoneal cavity.
[0177] Embodiment 33
[0178] The difference between Example 33 and Example 24 is that:
[0179] The macrophages are primary monocytes derived from stem cells.
[0180] Embodiment 34
[0181] The present invention discloses a method for preparing monocytes or macrophages loaded with attenuated Salmonella modified with RGD peptides and its application, wherein the monocytes or macrophages (including THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., as well as primary monocytes / macrophages of human / mouse origin) and RGD peptide packaged lentivirus (prepared by transfecting 293T / 293FT cells with packaging plasmids and expression plasmid vectors) are added with the packaged prepared lentivirus according to MOI 5-50. After 24-72 hours of virus infection, RGD peptide-modified stable engineered immune cells are obtained by screening using fluorescent markers (green fluorescence GFP) or eukaryotic antibiotic resistance (puromycin 1-6 μg / mL). Compared with normal monocytes / macrophages, the modification of RGD peptides effectively improves the adhesion ability of cells to tumor cells, thereby improving the intratumoral enrichment performance of cells.
[0182] The RGD peptide-modified monocytes or macrophages are co-cultured with attenuated Salmonella typhimurium at an MOI of 1-100 for 20-120 minutes to obtain engineered cells loaded with attenuated Salmonella. RGD peptide modification does not affect the biological activity of the cells (including chemotaxis, phagocytosis, etc.), and the attenuated Salmonella in the cells can maintain biological activity, and after being released again in vitro, it can reach a growth plateau within 24 hours. Compared with single injection of attenuated Salmonella, single RGD peptide-modified monocytes / macrophages, and attenuated mixtures of RGD peptide-modified monocytes / macrophages and attenuated Salmonella, after camouflage protection and targeted delivery of bacteria by RGD peptide-modified monocytes / macrophages for tumor treatment, the tumor growth of mice was more significantly inhibited and the survival time was significantly prolonged.
[0183] The attenuated Salmonella typhimurium is attenuated Salmonella typhimurium VNP20009 and its genetically modified strains and synthetic biology modified engineering strains that can produce drug proteins; the monocyte cell line / macrophage cell line used for RGD peptide modification includes but is not limited to macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, and primary monocytes / macrophages of human / mouse origin, etc.
[0184] The invention discloses a method for preparing a monocyte cell line or macrophage cell line modified with RGD peptide and loaded with attenuated Salmonella, and an application thereof in anti-tumor treatment.
[0185] The therapeutic dose of engineered monocytes / macrophages loaded with attenuated Salmonella modified with RGD peptide was 0.4-40×10 5 The unit is cell / mouse, corresponding to the actual amount of attenuated Salmonella is 0.1-10×10 6 The unit is CFU / mouse. The RGD peptide-modified engineered monocytes / macrophages loaded with attenuated Salmonella are administered only once, and the administration method is mainly intravenous or intraperitoneal injection.
[0186] The engineered monocytes / macrophages modified with the RGD peptide and loaded with attenuated Salmonella are mainly administered by intravenous injection for treatment, and can also be administered by intraperitoneal injection or intratumoral injection depending on the type of tumor.
[0187] Compared with unmodified macrophages, engineered macrophages modified with RGD peptide showed a 2.5-fold improvement in the recognition and enrichment of mouse breast cancer lung metastases within 2 hours after intravenous injection.
[0188] Compared with a single injection of attenuated Salmonella and a simple mixture of RGD-modified engineered macrophages and attenuated Salmonella, the camouflage protection and targeted delivery of the bacteria by macrophages achieved an increase of 410.5% in the titer of Salmonella in lung tumors within 4 hours after administration, a decrease of 61.8% in the off-target effects of normal organs, and a reduction of >90% in the area of liver lesions.
[0189] The RGD-modified macrophages, the chemotaxis of the macrophages themselves to the tumor area, and the enrichment effect of the cells enhanced after RGD modification are key factors in achieving tumor targeting of this type of drug.
[0190] The attenuated Salmonella typhimurium VNP20009 and its genetically modified strains delivered and released to tumor tissues via RGD-modified cells are key factors in exerting the anti-tumor efficacy of this type of drug.
[0191] The monocytes / macrophages that can be used for genetic engineering transformation include, but are not limited to, macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from peritoneal cavity, monocytes / macrophages induced and differentiated from stem cells, etc., all of which are suitable for such preparation and application schemes. The following test examples are described with the classical macrophage cell line RAW264.7 as a specific object.
[0192] Embodiment 35
[0193] Construction and characterization of RGD peptide-modified chassis macrophages (abbreviated as R-GEM)
[0194] In order to stably express arginine-glycine-aspartic acid (RGD) peptide on the membrane of RAW264.7 macrophages, the present invention transforms macrophages through a lentiviral packaging method. RGD specifically binds to integrin αv and its heterodimers highly expressed on the surface of tumor cells, and has been widely used in preclinical and clinical studies to improve the tumor enrichment effect of different drugs. Similar to the construction of CAR-M cells, macrophages are transduced with a lentiviral vector with a CAR-like structure. The RGD peptide (ACDCRGDCFCG) was synthesized by GenScript, in which the EF1α eukaryotic promoter, CD8 signal peptide and Myc tag were sequentially inserted into the 5' end of RGD, and the CD8 hinge and transmembrane domain (i.e., CD8 transmembrane peptide) were inserted into the 3' end. The CD8 signal peptide and the CD8 hinge and transmembrane domain successfully localize RGD to the cell outer membrane. The Myc tag helps to detect the expression and localization of the RGD peptide ( Figure 1A). All fragments were cloned and inserted into the third-generation lentiviral plasmid pLenti by homologous recombination. Lentivirus packaging plasmids (pMDLg / pRRE, pRSV-Rev), membrane protein expression plasmids (pMD2G) and RGD functional plasmids were co-transfected into 293FT cells using a transfection reagent. The supernatant containing the lentivirus was collected on days 1, 2 and 4 after transfection and filtered with a 0.45 μm filter. The viral particles produced by the cells were concentrated and purified by ultracentrifugation, and then co-cultured with macrophages RAW264.7 at an MOI of 15 for 72 hours. Finally, the present invention obtained genetically engineered macrophages (abbreviated as R-GEM cells) whose cell membrane surface was modified with RGD peptides through eukaryotic cell resistance screening ( Figure 1A , Figure 1B ).
[0195] The nucleotide sequence of the CD8 signal peptide is shown in SEQ ID NO. 1. The nucleotide sequence of the myc tag is shown in SEQ ID NO. 2. The nucleotide sequence of the RGD peptide is shown in SEQ ID NO. 3. The nucleotide sequence of the EF1α promoter is shown in SEQ ID NO. 4. The nucleotide sequence of the CD8 transmembrane peptide is shown in SEQ ID NO. 5.
[0196] To confirm the successful localization of the RGD peptide on the cell membrane, R-GEM cells were seeded into 12-well plates, the culture medium was discarded and the cells were rinsed with PBS, first incubated with 1% BSA in PBS to block nonspecific binding sites, and co-incubated with anti-Myc primary antibody on ice. After rinsing the cells with PBS 2-3 times, they were stained with IgG (H+L) fluorescent secondary antibody under light-proof conditions. The macrophage nuclei were stained with the nuclear dye Hoechst, and the images were observed and taken using a fluorescence microscope. The results showed that a significant red fluorescent signal was observed on the surface of the cell outer membrane ( Figure 1C ), which confirmed that the RGD peptide was effectively localized on the surface of the outer membrane of the engineered macrophages of the present invention.
[0197] In order to determine whether RGD expressed on the surface of macrophages would target them to cells expressing αvβ3 integrin on the cell membrane, various αvβ3-positive tumor cells, including breast cancer cell 4T1, melanoma cell B16F10 and colorectal cancer cell MC38, were cultured at 1×10 5The cells were inoculated into a 96-well plate at a high density and cultured overnight. R-GEM cells labeled with the cell membrane red fluorescent dye DiI were then co-cultured with these tumor cells for 10 seconds or 10 minutes, after which the culture supernatant was removed and the total fluorescence was quantitatively detected using an enzyme reader. Theoretically, macrophages that do not adhere to tumor cells or macrophages with weak adhesion are eliminated in large numbers. Genetically engineered macrophages transduced with an empty lentivirus (called B-GEM) were used as a control for comparison. Compared with B-GEM cells, R-GEM cells had a significantly higher binding rate to various αvβ3-positive tumor cells, and the binding rates to 4T1, B16F10 and MC38 cells were increased by 1.8 times, 2.0 times and 2.4 times, respectively ( Figure 1D ).
[0198] In order to further evaluate the role of RGD peptide in mediating the adhesion of macrophages to tumor cells, in the exogenous RGD peptide competitive blocking adhesion test, different concentrations (including 0 / 1 / 2 / 4 / 8 μM) of RGD peptide (MCE, HY-PO278, Shanghai, China) were incubated with tumor cells for 30 minutes, and then R-GEM labeled with cell membrane red fluorescent dye DiI was added according to the same steps as above, and the adhesion of macrophages to tumor cells was detected after 10 minutes of incubation. The changes in the number of adherent macrophages were quantitatively compared using an enzyme marker (BioTek). The results showed that after the addition of free synthetic RGD peptide, the binding efficiency of R-GEM to tumor cells was significantly reduced. When the concentration of free RGD was as high as 8 μM, the binding of R-GEM to tumor cells was restored to the same level as B-GEM ( Figure 1E These results confirmed that the binding of R-GEM to tumor cells can indeed be enhanced, and this enhancement is dependent on the expression of RGD peptide on the extracellular surface of cells.
[0199] In order to verify the targeted chemotactic effect of R-GEM cells on tumor metastases in vivo, the present invention first detected the chemotactic response of R-GEM cells to chemokine CCL2 in vitro. The results of the Transwell test showed that R-GEM cells maintained their original high-efficiency chemotactic performance ( Figure 1F ). Subsequently, the present invention tested the ability of R-GEM cells to target lung tumor metastases. The present invention injected DiR dye-labeled R-GEM cells into mice with 4T1 tumor cell metastasis through the tail vein. The results of in vivo imaging showed that several macrophages were effectively enriched in lung cancer metastases ( Figure 1G , Figure 1H ). It is noteworthy that R-GEM cells have a 2.5-fold higher enrichment efficiency in tumor metastases compared to B-GEM cells ( Figure 1G , Figure 1H ), which is consistent with its excellent tumor cell adhesion properties ( Figure 1D). This enhanced tumor region enrichment ability makes R-GEM cells a potential new type of chassis macrophage for tumor-targeted drug delivery.
[0200] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0201] Test Example 1
[0202] Preparation and preliminary evaluation of RGD peptide-modified macrophages loaded with anti-tumor bacteria
[0203] In order to prepare R-GEM cells loaded with VNP20009 or its genetically modified strain (named R-GEM / VNP cells), the engineered macrophage R-GEM prepared above was co-incubated with the VNP20009 strain. Specifically, R-GEM cells with good growth conditions were cultured at 5×10 5 The cells were inoculated into 6-well plates at a ratio of 100 / well and cultured in cell culture medium without antibiotics. VNP20009 or its genetically modified strain monoclonal strain was picked from the agar plate and activated overnight in LB liquid medium. The bacterial solution cultured to the logarithmic growth phase was centrifuged at 8000 rpm for 5 minutes, the supernatant was discarded and the precipitate was resuspended in sterile saline. After adjusting the OD600 to 1.0, the bacteria were added to the 6-well plate containing the above cells (MOI 10) and co-cultured for different time periods. The strain VNP20009 or its genetically modified strain can actively infect cells, and macrophages can also phagocytize the strain ( Figure 2A ). In order to detect the number of VNP20009 or its genetically modified strains effectively loaded in macrophages, the number of live R-GEM / VNP cells at different time points was detected with the help of a cell counter, and then the cells were lysed with 0.5% Triton X-100 at room temperature. The lysate was diluted in multiples, applied to LB agar plates containing kanamycin, and incubated at 37°C overnight. The total number of live bacteria loaded into the cells was counted. As the co-culture time increased, the number of VNP20009 or its genetically modified strains in the R-GEM / VNP cells continued to increase, but the biological activity of the macrophages decreased, which may be due to the continuous stimulation of bacteria ( Figure 2B). 60 min of co-culture was chosen as a suitable time because the number of bacteria loaded intracellularly was appropriate (approximately 294 bacteria per 100 cells) and the macrophages maintained a high survival rate (>90%) ( Figure 2B ).
[0204] In order to observe the morphological changes of R-GEM / VNP cells and their load on intracellular strains, an engineered strain VNP-RFP that can express red fluorescent protein (RFP) was used to prepare R-GEM / VNP-RFP cells. The cells were fixed with 4% paraformaldehyde, and then the cytoskeleton was labeled with Actin-Tracker Green-488 (Beyotime, C2201S, Shanghai, China). Normal cells were stained with Hoechst, and paraformaldehyde-fixed cells were stained with DAPI. B-GEM cells were used as negative controls. Finally, the cells were photographed and recorded using a fluorescence microscope (Zeiss). At the same time, the morphology of R-GEM / VNP cells was observed using a transmission electron microscope (TEM). R-GEM / VNP cells were pre-fixed in 2.5% isopropanol at 4°C for 2-4 hours and washed with 0.1M phosphate buffer (pH 7.4). Then, the samples were suspended and embedded in 1% agarose, fixed with 1% osmium acid in 0.1 M phosphate buffer (pH 7.4) for 2 hours, and rinsed several times with 0.1 M phosphate buffer (pH 7.4) at room temperature. After fixation, dehydration with a series of graded ethanol, the samples were embedded in Epon812, polymerized in a 60 ° C oven for 48 hours, sliced with an ultramicrotome, with a thickness of 60-80 nm, and double-stained with 2% uranyl acetate and 2.6% lead citrate for TEM observation. Fluorescence microscopy observation ( Figure 2C ) and transmission electron microscopy ( Figure 2D ) results confirmed that R-GEM / VNP cells and their intracellular bacteria maintained their original complete biological structure.
[0205] In order to detect the long-term survival of intracellular bacteria, macrophages loaded with different strains were cultured continuously in a medium supplemented with gentamicin for 3-24 hours, and then the cells were collected and counted. After adjusting to the same cell number, 0.5% Triton X-100 was added, and the cells were fully lysed in combination with a tissue grinder. After breaking the membrane, the supernatant was diluted and spread on the corresponding solid LB agar plate for culture and counting. The changes in the number of intracellular bacteria were detected and it was found that the VNP strain in the cell maintained efficient biological activity and continued to proliferate ( Figure 2E ). All these findings lay the foundation for efficient cell-mediated tumor-targeted bacterial delivery.
[0206] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0207] Test Example 2
[0208] Evaluation of the bioactivity of RGD-modified anticancer bacteria-loaded macrophages
[0209] (1) Detection of intracellular activity and release of RGD-peptide-modified macrophage strains loaded with anticancer bacteria
[0210] In order to detect the release of intracellular bacteria by cells, the present invention uses an engineered strain (psifB-RFP-VNP) that can express red fluorescent protein (RFP) shortly after entering the cell (within 30 minutes) to explore the release dynamics of VNP strains in R-GEM / VNP cells ( Figure 3A ). R-GEM / psifB-RFP-VNP cells were continuously cultured in a medium supplemented with gentamicin, and some oncogenic / ruptured macrophages were observed during the culture period. Activated bacteria (expressing RFP) were observed near these oncogenic / ruptured macrophages, and the number of released bacteria increased over time ( Figure 3B , C). Only a suitable extracellular environment can enable the released bacteria to proliferate effectively, thus ensuring the effectiveness and safety of this strategy ( Figure 3C ).
[0211] In order to detect the changes in the proliferation activity of VNP20009 or its genetically modified strains released from R-GEM / VNP cells, after obtaining R-GEM / VNP cells, 0.5% Triton X-100 was used to lyse the cells and release the intracellular strains. The VNP strain in the supernatant was collected as the released strain. Subsequently, the growth curves of the normal strain and the released strain on the liquid LB medium were detected using the Bioscreen C software (OY Growth175Curves Ab Ltd., Finland). Specifically, 10 μL VNP20009 suspension (OD600 = 1.0) was added to 1 mL LB medium, and after thorough mixing, 300 μL of culture solution was added to each well of the Bioscreen C multiwell plate. The multiwell plate was incubated at 37°C for 30 hours. Every 30 minutes, the OD value was measured using a brown filter with a wavelength of 600 nm. The results confirmed that the normal strain and the released strain had similar proliferation and growth characteristics and could grow to the plateau phase within 24 hours ( Figure 3D ).
[0212] In order to detect the activation of macrophages by VNP20009 or its genetically modified strains released by R-GEM / VNP cells, the released VNP20009 strains and the normally cultured VNP20009 or its genetically modified strains were co-cultured with the M0 type macrophage cell line RAW264.7 (MOI 10, 6 hours). Untreated macrophages were used as blank controls. Subsequently, the incubated cells were collected using the FreeZol reagent in the RNA extraction kit (Vazyme, R711-02), the total cell RNA was extracted, and it was resuspended in RNase-free ddH2O to adjust the RNA concentration. The extracted total RNA was reverse transcribed into cDNA using a reverse transcription kit (ThermoScientific, M16315). Finally, the qPCR mixture (Vazyme, Q111-02), the prepared cDNA and different primers were mixed separately. Then, the mRNA level was quantified using the real-time fluorescence quantitative PCR instrument QuantStudio 3. The results showed that both normal strains and released strains could effectively induce M1 transformation of macrophages, and the mRNA levels of the corresponding series of pro-inflammatory factors were significantly upregulated (including IL1b, IL6, TNFa, IL23a, NLRC4 and NOS2) ( Figure 3E ).
[0213] Salmonella can directly induce apoptosis of tumor cells. Next, the ability of VNP20009 or its genetically modified strains released by R-GEM / VNP cells to infect tumor cells and induce apoptosis was tested. 5) were inoculated on a 12-well plate and cultured for 6 to 8 hours. Then, normal VNPs or released VNPs or their genetically modified strains were collected and co-cultured with cells at an MOI of 100 for 4 hours. All cells in the plate were removed, washed, and then 1 μL of propidium iodide (PI, 25 g / mL) was added to all prepared samples, gently mixed and detected by flow cytometry. The results showed that compared with less than 5% of apoptotic cells in the saline group, normal VNPs or released VNP strains could induce significant apoptosis in tumor cells, and the apoptosis levels were all higher than 20%, while there was no significant difference between the two bacterial groups ( Figure 3F ).
[0214] These results indicate that the intracellularly released VNP strains have no significant differences from normal VNP strains in terms of growth rate, activation of immune cells, and induction of tumor cell necrosis. Therefore, when present in tumors, these released VNP strains can reshape the tumor microenvironment in a classic manner and promote tumor regression.
[0215] (2) Detection of RGD peptide-modified macrophages loaded with anticancer bacteria
[0216] In order to detect the changes in a series of macrophage intrinsic biological activities of R-GEM / VNP cells, including the production level of tumor cell killing factors, tumor cell killing ability, chemotaxis ability, etc. For the detection of the production level of tumor cell killing factors of R-GEM / VNP cells, cDNA of R-GEM / VNP cells and other cells was obtained according to Experimental Example 3(1). Then, the mRNA level was quantified using the real-time fluorescence quantitative PCR instrument QuantStudio 3. The results showed that the mRNA expression levels of cytokines with direct or indirect anti-tumor effects (including IL1b, IL6, TNFa, MCP1 and RANTES) were significantly increased ( Figure 4A In addition, the production of ROS and NO in R-GEM / VNP cells increased by 1.8 and 2.0 times, respectively, compared with that in R-GEM cells ( Figure 4A ). To detect the killing activity of macrophages against tumor cells, 4T1 cells expressing green fluorescent protein (4T1-GFP) were cultured at 2×10 5 The cells were seeded at a density of 100 cells / well in a 12-well plate and cultured in a cell culture incubator for more than 8 h to ensure complete cell adhesion. Subsequently, 2 × 105 R-GEM or R-GEM / VNP cells were placed in a 0.4-μm Transwell chamber (Labselect, 14211, Beijing, China) for indirect co-culture of tumor cells and macrophages ( Figure 4C). After continuous culture in the cell culture incubator for 18 hours, the culture dish was removed and stained with PI and Hoechst for 30 minutes at 37°C. Finally, the proliferation activity and number of tumor cells in the lower chamber were photographed using a fluorescence microscope. The fluorescence intensity of GFP and PI was measured using an enzyme marker for quantitative comparison. During the period, the growth and proliferation of tumor cells at different incubation time points were detected simultaneously (indirectly monitored by detecting the green fluorescence intensity of 4T1-GFP cells in the lower chamber). The results showed that R-GEM / VNP cells achieved a more potent killing effect on tumor cells ( Figure 4C ), consistent with the potent growth inhibitory effect on tumor cells ( Figure 4D ). The chemotactic performance of engineered macrophages was tested by using the Transwell assay in reference to Experimental Example 1. The results showed that R-GEM / VNP cells showed stronger chemotactic performance to the chemokine CCL2 than R-GEM cells ( Figure 4E ).
[0217] In summary, these results indicate that R-GEM / VNP cells have strong chemotactic and tumor cell-killing properties. VNP20009 or its genetically modified strains can be delayed released by R-GEM / VNP cells, and the released VNP strains also exhibit classic anti-tumor efficacy.
[0218] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0219] Test Example 3
[0220] In vivo biological performance testing of RGD peptide-modified macrophages loaded with anti-tumor bacteria
[0221] Establishment of 4T1 lung metastasis mouse model
[0222] 4T1 cells were continuously cultured in DMEM medium supplemented with 10% fetal bovine serum, and then tumor cells were collected and injected into 6-week-old female BALB / c mice via the tail vein (5×10 5 Subsequent experiments were performed after the initial formation of tumor cell metastases in the mouse lungs (approximately 4-6 days).
[0223] Dosage
[0224] Different macrophages were treated with near-infrared (NIR) fluorescent dye DiR (Abbkine, BMD0074, Wuhan, China) for 30 min to produce DiR-labeled cells. Tumor-bearing mice were randomly divided into groups and different macrophages (2 × 10 per mouse) were used to generate DiR-labeled cells. 5 cells, including B-GEM and R-GEM), VNP20009 or its genetically modified strains (5×10 5 CFU), engineered macrophages loaded with VNP20009 (2×10 per mouse 5 Cells, including B-GEM / VNP and R-GEM / VNP) and a simple mixture of engineered macrophages and VNP or its genetically modified strains (R-GEM+VNP) were intravenously administered to tumor-bearing mice. Lung metastasis model mice injected with an equal amount of saline were used as a control group. The above-mentioned VNP20009 or its genetically modified strains include the VNP-LuxCDABE strain constructed in the early stage of the laboratory, which can spontaneously generate bioluminescence for in vivo tracing; and the strain VNP-NC carrying an empty plasmid.
[0225] The cells were injected into 4T1 lung metastasis-bearing mice via the tail vein. Lumina III, Waltham, MA, USA) detected the fluorescence signals of LuxCDABE and DiR in mouse tumors after different treatment methods / times. The results showed that the single strain was initially enriched in normal organs such as spleen and liver ( Figure 5A Notably, macrophage-based delivery (including B-GEM / VNP and R-GEM / VNP) significantly reduced off-target localization of bacteria in normal organs ( Figure 5A This may be attributed to the fact that in the absence of macrophage-mediated protection, VNPs of a single VNP group or their genetically modified strains would be rapidly cleared by immune cells (such as neutrophils) in the body ( Figure 5B ). It is worth noting that the R-GEM / VNP group had a better tumor enrichment effect on the VNP strain, with bacterial enrichment increasing by 3.8 times and 1.5 times compared with the VNP group and the B-GEM / VNP group three hours after administration, respectively ( Figure 5A ). In addition, simply mixing R-GEM cells with VNP strains (R-GEM+VNP group) did not achieve the same bacterial tumor enrichment enhancement effect as the R-GEM / VNP group ( Figure 5A ), indicating that the enhanced targeting efficacy is indeed derived from R-GEM cell-based post-loading delivery. Within 4 hours after administration, the fluorescence intensity of R-GEM cells in lung tumors reached a peak ( Figure 5CCompared with R-GEM+VNP cells, R-GEM / VNP cells showed higher efficiency in sustained targeted delivery of VNP strains to metastatic foci ( Figure 5D ), highlighting the superiority of this delivery system.
[0226] In order to detect the distribution of bacteria released in lung tissue after R-GEM / VNP cells arrived at lung metastases, 4T1-GFP cells were injected into BALB / c mice via the tail vein. After tumor foci appeared in the lungs, mice were injected with engineered macrophages (R-GEM / VNP-RFP) through the same route. After 12 hours of treatment, lung tissue was harvested, rinsed with PBS, and embedded with optimal cutting temperature (OCT) compound (Servicebio, G6059). Sections with a thickness of 10 μm were prepared using a freezing microtome (Leica Biosystems, Wetzlar, Germany), stained with DAPI, and observed in detail under a fluorescence microscope (Carl Zeiss, Axioplan 2, Oberkochen, Germany). The results showed that a large number of released VNP-RFP strains could be observed in tumor tissues, while in normal tissues, there were basically no strains ( Figure 5E ). This emphasizes the superiority and specificity of R-GEM cells as drug (bacterial) delivery vehicles.
[0227] In order to detect the number of bacteria delivered by R-GEM / VNP cells to tumor metastases, the present invention measured the total number of bacteria in the lungs after administration of different doses by the dilution coating method, and then divided it by the average number of mouse lung lesions, and finally calculated the average number of bacteria delivered to the metastases by the R-GEM / VNP delivery system. In order to reduce the error caused by the self-reproduction of released bacteria in the tumor, the present invention uses gentamicin to eliminate free bacteria without affecting the survival of bacteria in the cells. At the same time, the lung tumor foci were photographed by in vivo imaging to detect the clearance of intratumoral strains. The results showed that the R-GEM / VNP system can deliver approximately 38 bacteria ( Fig. 5F After a single injection, the VNP strain could be detected at the tumor site for more than 18 days ( Figure 5G ). These results indicate that RGD peptide-engineered macrophages can indeed be used to load the anti-tumor bacteria VNP20009 or its genetically modified strains and effectively enhance the initial enrichment of bacteria in lung metastases in vivo.
[0228] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0229] Test Example 4
[0230] Biosafety Assessment of 5RGD Peptide-Modified Macrophages Loaded with Anticancer Bacteria
[0231] The 4T1 lung metastasis mouse model was established as described in Experimental Example 4.
[0232] Dosage
[0233] Tumor-bearing mice were randomly divided into groups and injected with different cells once via tail vein. The dosage of different macrophages (2×10 5 cells, including B-GEM and R-GEM), different engineered strains (5×10 5 CFU, including VNP-lux and VNP-NC, VNP-loaded macrophages (2×10 per mouse 5 Cells, including B-GEM / VNP and R-GEM / VNP) and a simple mixture of macrophages and VNP. Only saline was injected as a negative control.
[0234] Acute toxicity assessment
[0235] Four groups of 4T1 lung metastasis-bearing mice were intravenously administered with physiological saline, single VNP20009 or its genetically modified strain, R-GEM / VNP cells, and R-GEM cells + VNP20009 strains, and blood was collected from the mouse orbits one day later (about 200 μL) to collect whole blood. The whole blood was placed at room temperature for 30 minutes and then centrifuged at 3000 rpm for 15 minutes. The supernatant serum was collected for blood biochemical tests including ALT and AST. At the same time, the normal organs of the mice (including heart, liver, spleen, and kidneys) were dissected and photographed, weighed, and HE-stained. The long-term changes in the weight of the mice were subsequently monitored.
[0236] The results showed that both single VNP20009 or its genetically modified strain and R-GEM cells + VNP20009 or its genetically modified strain group induced significant liver damage, manifested as obvious foci on the liver surface ( Fig. 6A), HE staining can observe obvious necrotic areas ( Figure 6B ). Biochemical indicators (ALT / AST) that are positively correlated with the degree of liver inflammation were significantly increased ( Figure 6B ), the spleen is significantly enlarged ( Figure 6C ). In contrast, all the above damage indicators of R-GEM / VNP cells were significantly alleviated. Specifically, the average number of acute liver lesions in the normal saline group was 0, the average concentrations of ALT and AST in serum were 46.0U / L and 36.1U / L, and the average total spleen volume was 0.1068g; the average number of acute liver lesions in the single VNP20009 or its genetically modified strain group was 7, the average concentrations of ALT and AST in serum were 147.8U / L and 145.0U / L, and the average total spleen volume was 0.1680g; the average number of acute liver lesions in the R-GEM cell + VNP20009 or its genetically modified strain group was 6, the average concentrations of ALT and AST in serum were 154.5U / L and 150.4U / L, and the average total spleen volume was 0.1716g; the average number of acute liver lesions in the R-GEM / VNP cell group was 1, the average concentrations of ALT and AST in serum were 56.7U / L and 45.3U / L, and the average total spleen volume was 0.1119g. However, no significant differences were observed in HE of other organs (including heart, spleen, lung, and kidney) among the above groups. Fig.6D The sudden weight loss of mice induced by VNP20009 or its genetically modified strains was also significantly alleviated in the R-GEM / VNP cell group ( Fig. 6E ). It can be seen that the loading and re-delivery of R-GEM cells can indeed reduce the toxic side effects caused by VNP20009 or its genetically modified strains and improve biosafety. However, this effect cannot be achieved by simply mixing R-GEM cells with VNP20009 or its genetically modified strains. This highlights the effectiveness of the strategy of the present invention.
[0237] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0238] Test Example 5
[0239] Evaluation of the anticancer effects of RGD peptide-modified macrophages loaded with anticancer bacteria
[0240] Six-week-old female BALB / c mice (Changzhou Animal Center) were used as experimental animals. The 4T1 lung metastasis mouse model was established by referring to the description in Experimental Example 4. Administration: Different cells were administered once via tail vein injection. The dosage was R-GEM cells (2×10 per mouse). 5 cells), single VNP strain (5×10 per mouse 5 strains), R-GEM+VNP (2×10 per mouse 5 cells and 5×10 5 strains) and R-GEM / VNP cells (2×10 per mouse 5 cells). Only saline was injected as a negative control. To observe the progression of lung tumors, mice were euthanized on the 12th day after different treatments were performed on the tumor lung metastasis mouse model, and lung tissues were collected for photography, weighing, and HE observation ( Fig. 7A ). The survival status of the mice was observed, and a mouse survival analysis curve was constructed. When the mice showed discomfort symptoms such as inability to eat or drink, separation of skin and subcutaneous tissue, lethargy, and disheveled hair, the mice were euthanized and recorded as dead. The results showed that compared with the average lung tissue weight of 0.50g, the number of tumor metastases of 66.3, and the median survival time of 22 days in the normal saline group, the single VNP strain group, the R-GEM / VNP group, and the R-GEM+VNP group all significantly hindered the progression of the tumor. Among them, the R-GEM / VNP group had a lung tissue weight of 0.34g (32.0% lighter than normal saline), a number of tumor metastases of 35.5 (46.4% less than normal saline), and a median survival time of 32.5 days (47.7% longer than normal saline) ( Figure 7B -D). The R-GEM / VNP group was able to maintain effective tumor treatment effects while achieving high biosafety, which not only demonstrated the effectiveness of R-GEM cells as a drug delivery chassis macrophage, but also confirmed that R-GEM cells can be used for tumor-targeted delivery of living anti-tumor drugs such as bacteria.
[0241] The present invention carried out the same experiment using macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, etc., monocyte cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, etc., primary monocytes / macrophages derived from human / mouse bone marrow, primary monocytes / macrophages in peripheral blood, primary monocytes / macrophages derived from the peritoneal cavity, and monocytes / macrophages induced and differentiated from stem cells, and obtained similar results (specific data are not provided repeatedly).
[0242] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and the scope of protection of the present invention is defined by the attached claims, description and their equivalents.
Claims
1. A method for preparing an engineered monocyte or macrophage loaded with attenuated Salmonella modified with RGD peptide, characterized in that The steps include: (1) using lentiviral transduction technology to package, infect, and screen the virus to transform wild-type monocytes or macrophages into genetically engineered cells that can express RGD peptides on the cell outer membrane surface; (2) co-culturing the genetically engineered cells with attenuated Salmonella typhimurium at a MOI ratio of 1-100 for 20-120 minutes to obtain RGD-modified engineered cells loaded with attenuated Salmonella, namely, RGD peptide-modified engineered monocytes or macrophages loaded with attenuated Salmonella.
2. The preparation method according to claim 1, characterized in that: In step (1), the monocyte / macrophage cell lines used for RGD peptide modification and intracellular strain loading include but are not limited to any one of THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, RAW264.7, J774.1, Ana-1, iBMDM, U937, and mouse / human primary monocytes / macrophages.
3. The preparation method according to claim 3, characterized in that: In step (1), the monocytes are any one of the monocytic cell lines THP1, iBMMC, J-111, Mono-Mac-1, JOSK-M, and primary monocytes derived from bone marrow, peripheral blood or stem cells; the macrophages are any one of the macrophage cell lines RAW264.7, J774.1, Ana-1, iBMDM, U937, and primary monocytes derived from bone marrow, peripheral blood, peritoneal cavity or stem cells.
4. The preparation method according to claim 1, characterized in that: In step (1), the RGD peptide is arginine-glycine-aspartic acid, which can specifically bind to the αvβ3 receptor highly expressed in tumor cells; the lentiviral solution prepared by packaging with 293T / 293FT cells is co-incubated with monocytes or macrophages to prepare RGD-modified engineered monocytes or macrophages loaded with attenuated Salmonella at an MOI of 5-50.
5. The preparation method according to claim 1, characterized in that: In step (2), the attenuated Salmonella typhimurium is attenuated Salmonella typhimurium VNP20009 and its genetically modified strains; RGD peptide-modified stably transfected engineered immune cells are obtained by fluorescent labeling or eukaryotic antibiotic resistance screening, and the cells are co-incubated with the attenuated Salmonella strain VNP20009 or its genetically modified strains, and gentamicin is used to eliminate the extracellular free strains to obtain RGD peptide-modified engineered monocytes or macrophages loaded with VNP20009 or its genetically modified strains.
6. An engineered monocyte or macrophage modified with RGD peptide and loaded with attenuated Salmonella, characterized in that: The engineered monocytes or macrophages are obtained by the preparation method according to any one of claims 1 to 5.
7. Use of an engineered monocyte or macrophage modified with RGD peptide and loaded with attenuated Salmonella in the preparation of an anti-tumor drug.
8. The use according to claim 6, characterized in that: The therapeutic dose of engineered monocytes or macrophages loaded with attenuated Salmonella modified with RGD peptide was 0.4-40×10 5 cells / mouse, corresponding to the actual amount of attenuated Salmonella is 0.1-10×10 6 CFU / mouse; single administration.
9. The use according to claim 7, characterized in that: The anti-tumor drug includes at least one of an intravenous injection preparation, an intratumor injection preparation or an intraperitoneal injection preparation.
10. The combined use of the engineered monocytes or macrophages modified with the RGD peptide and loaded with attenuated Salmonella according to claim 1 and other conventional anti-tumor drugs or methods.
